Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents >= 6 to < 18 years of age

Rimegepant 312

Condition: Neurology
Phase: III
Clinicaltrials.gov ID: NCT04743141

What is the goal of the study?

To evaluate the safety and tolerability of rimegepant in children and adolescents (age >= 6 to < 18 years of age).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Heidi Blume
Study Team Member: Mikaela Gatterman, Mikaela.Gatterman@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.